Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Arrowhead Research Corp. Shares Surged

By Sean Williams - Mar 5, 2014 at 2:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Arrowhead gets a double-dose of analyst coverage before the opening bell. Here's what you should really be focused on instead.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Arrowhead Research ( ARWR -1.57% ), a clinical-stage biopharmaceutical company developing RNAi-based therapeutics, surged by as much as 29% after RBC Capital analyst Michael Yee, and Deutsche Bank analyst Alethia Young, initiated coverage on the company.

So what: Before the opening bell, RBC Capital analyst Michael Yee started coverage on Arrowhead with an outperform rating and a price target of $35, implying 66% upside based on yesterday's closing price. The coverage initiation comes on the heels of an OK for the company to begin a pivotal phase 2a trial of its hepatitis-B drug, ARC-520, on Monday. Yee believes there could be blockbuster potential for ARC-520. Similarly, Young initiated coverage on Arrowhead with a buy rating, and an even more robust $45 price target, implying 113% upside from yesterday's close. Young, according to Investor's Business Daily, estimates ARC-520's peak sales potential at $5.2 billion.

Now what: As a reminder, analyst actions rarely have any bearing on our long-term investing thesis, so it's probably best not to chase this move higher, or focus on their price targets. Instead, we should let ARC-520 and the remainder of Arrowhead's pipeline do the talking. For now, we're dealing with a very early stage experimental therapy which, as of now, has merely been tested for safety. It remains to be seen if ARC-520 can translate into the efficacy that Yee and Young are expecting, but I'd suggest, at least early on, that much of that optimism has already been baked into Arrowhead's share price.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arrowhead Pharmaceuticals, Inc. Stock Quote
Arrowhead Pharmaceuticals, Inc.
ARWR
$70.05 (-1.57%) $-1.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
673%
 
S&P 500 Returns
142%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.